万邦德：公司在研的小分子多肽新药已取得良好的前期数据

Core Viewpoint - The company is advancing a small molecule peptide drug targeting obesity and diabetes, currently in the preclinical stage, with promising preliminary data and plans for clinical translation [1] Group 1: Drug Development - The small molecule peptide drug shows different targets and mechanisms of action compared to GLP-1 drugs like Semaglutide [1] - Preclinical data indicates the drug not only aids in weight loss and fat burning but also reduces muscle loss, lowers blood sugar, and has anti-inflammatory effects [1] - The drug significantly improves multiple metabolic indicators, particularly demonstrating superior weight loss efficiency in studies involving diabetic obese mice compared to Semaglutide [1]